Methimazole
Treatment for Hyperthyroidism
Typical Dosage: Initial: 10-30 mg daily; Maintenance: 5-15 mg daily
Effectiveness
85%
Safety Score
55%
Clinical Trials
31
Participants
80K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
Initial: 10-30 mg daily; Maintenance: 5-15 mg daily
Time to Effect
1-2 weeks for symptom improvement, 4-8 weeks for hormone normalization
Treatment Duration
12-18 months typically, can be lifelong
Evidence Quality
HIGHNumber Needed to Harm (NNH)
2500(Treat 2500 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$900
Side Effect Mgmt:$100
Total Annual:$1,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$45,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$1,333
Cost per Remission
$2,400
Methimazole Outcomes
for Hyperthyroidism
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+90%
Remission Rate
+50%
Common Side Effects
Rash/itching
+15%
Arthralgia/myalgia
+5%
Nausea/vomiting
+5%
Agranulocytosis
+0.5%
Hepatotoxicity
+0.1%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
4 active trials recruiting for Methimazole in Hyperthyroidism
A Clinical Study of Hyperthyroidism in Children
NCT06570967RECRUITING
1K participants
OBSERVATIONAL
Shenyang, China
Started: Jul 18, 2023
Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
NCT07369063RECRUITINGPHASE2
30 participants
INTERVENTIONAL
New Hyde Park, United States
Started: Aug 1, 2025
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
NCT05461820RECRUITINGPHASE4
240 participants
INTERVENTIONAL
Nanjing, China
Started: May 1, 2018
A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
NCT07040306RECRUITING
1K participants
OBSERVATIONAL
Shenyang, China
Started: Nov 14, 2012
Completed Clinical Trials
9 completed trials for Methimazole in Hyperthyroidism
Comparative Study of mMASI Before and After Hyperthyroid Therapy in Hyperthyroid Subjects With Melasma
NCT04346901COMPLETEDPHASE1
23 participants
INTERVENTIONAL
Jakarta, Indonesia
Started: Aug 1, 2019
The Role of Thyroid Status in Regulating Brown Adipose Tissue Activity, White Adipose Tissue Partitioning and Resting Energy Expenditure
NCT03064542COMPLETED
30 participants
OBSERVATIONAL
Singapore, Singapore
Started: Oct 13, 2015
Hyperthyroidism: Methimazole Plus L-carnitine and Selenium
NCT04946123COMPLETEDNA
60 participants
INTERVENTIONAL
Torino, Italy
Started: Jul 5, 2021
Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients
NCT01560299COMPLETEDNA
150 participants
INTERVENTIONAL
Mashhad, Iran
Started: Feb 1, 2010
Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole
NCT02727738COMPLETEDNA
30 participants
INTERVENTIONAL
Pisa, Italy
Started: Jan 1, 2014
Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis
NCT05118542COMPLETEDPHASE3
36 participants
INTERVENTIONAL
Jakarta Pusat, Indonesia
Started: Jan 1, 2019
Antithyroid Drugs During Radioiodine Therapy
NCT00150137COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Odense, Denmark
Started: Jan 1, 2003
Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease
NCT02376088COMPLETED
328 participants
OBSERVATIONAL
Started: Jun 1, 2011
Block-replacement Therapy During Radioiodine Therapy
NCT00150124COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Odense, Denmark
Started: Jan 1, 2003
Showing 20 of 32 total trials